The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
about
Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase InhibitorsIdentification of a Hydrophobic Cleft in the LytTR Domain of AgrA as a Locus for Small Molecule Interactions That Inhibit DNA BindingDiscovery of fragment molecules that bind the human peroxiredoxin 5 active siteComputer-aided design of fragment mixtures for NMR-based screeningSmall-molecule inhibitors of protein-protein interactions: progressing towards the dreamCharting biologically relevant chemical space: a structural classification of natural products (SCONP)Recent contributions of structure-based drug design to the development of antibacterial compounds.NMR-based analysis of protein-ligand interactions.NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.Discovering novel ligands for macromolecules using X-ray crystallographic screening.Use of 19F NMR spectroscopy to screen chemical libraries for ligands that bind to proteins.Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer-aided molecular design I: discovery of anticancer compounds.Estimating protein-ligand binding affinity using high-throughput screening by NMR.A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinasesExperimental validation of a fragment library for lead discovery using SPR biosensor technology.Fragment screening of infectious disease targets in a structural genomics environmentEmerging role of surface plasmon resonance in fragment-based drug discovery.Fragment-based screening by protein crystallography: successes and pitfalls.An integrated fragment based screening approach for the discovery of small molecule modulators of the VWF-GPIbα interaction.Perspectives on NMR in drug discovery: a technique comes of ageStructure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid.NMR-based techniques in the hit identification and optimisation processes.Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery.A decade of fragment-based drug design: strategic advances and lessons learned.High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands.Mycofactocin-associated mycobacterial dehydrogenases with non-exchangeable NAD cofactors.Computational medicinal chemistry in fragment-based drug discovery: what, how and when.Fragment informatics and computational fragment-based drug design: an overview and update.Recent applications of isotopic labeling for protein NMR in drug discovery.Fragment-based drug discovery using the SHAPES method.Mapping the surface of Escherichia coli peptide deformylase by NMR with organic solvents.SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1.Determination of the binding epitope of lidocaine with AGP: minimizing the effects of nonspecific binding in saturation transfer difference experiments.Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD).Computational Methods to Support Fragment-based Drug Discovery
P2860
Q27649995-79988944-F7D6-4363-8BB9-450BC2FB76CAQ27675241-437446C2-3079-449D-AE6A-B4A16BC42F73Q28473225-93FA2F72-EFC5-45ED-9A1F-AC07DD9F589FQ28487948-D0BC0CF1-4645-45D7-BF47-BD44B2617FA7Q29617758-512CF8A3-7589-415C-920C-4D31D94EC98AQ30351855-9FD04450-6F34-45F7-8557-F9F4F79BC10CQ30380194-595A979C-626A-402E-A9EC-BA9E9158B93BQ30617417-B6ACFB02-EF49-4858-8B92-E56517A36C2EQ30788870-CB0A7D82-BABD-498D-9670-8E8C321EAF80Q30936130-53562B2F-F088-4B19-BC38-9D83B1697A9BQ31050989-D528DA75-CD4F-4E2C-B31A-3D4080375825Q31166374-768D4244-D59A-4104-9C9B-9C5CD1BF58BBQ33373482-2D3C0119-E6DF-4004-9211-AAE58DB46526Q33738068-9255DD7E-BBC0-476E-8AFA-2E7A205B51F6Q33768454-CEA0BF9B-725D-4729-86FC-4586B1CAAF8BQ33836468-CB8447A0-346A-44FA-B925-D13EDE2808CAQ34049517-14F601B8-D806-48DE-B70B-869AF871D422Q34314898-30DB23E0-C7E6-4853-BE7C-78628D466F84Q34448727-3749683F-36CE-4B34-B09D-CD5D9CF02D3CQ34930997-373355F8-13D5-4D17-BE2F-B8A24C2799BDQ35033809-7A81BFD7-CE87-42BC-9C86-B45BC60B6E4FQ35976375-D57A682C-BA69-4BCB-AA99-97B64F728B21Q36416631-E124E0C6-FAED-4EA2-8F64-FE1D55FE2F7AQ36732253-7A5DFE7A-5038-4D2C-B5F0-A7E17F4ECB28Q37019374-8C440B76-B3C6-4F56-875D-E0E6A33865CDQ37605165-0C505E24-AC05-448A-A383-40ED6CE0C385Q37856296-B7DB07C3-9725-4820-8F34-3EE2051ED23BQ37995087-34CC038C-119C-42F5-B46B-D6E950AF4C6AQ38088423-3CE697C5-DD4B-4495-BE8E-F666683EC60FQ38089130-443682BD-99A3-4A0A-B4C4-134890B7794CQ38270124-73B1DB2F-07C2-4D8E-9F8D-B5C996692C1EQ38281136-56CEBBC6-CD4D-4B1D-82BB-97A560FAEB58Q46416497-31CE3339-F2C0-4E32-8A12-30F98705AE89Q53177201-9EEA2C87-CAA7-4277-8EB8-454CDA6BF630Q58488998-1DB170E5-D983-418C-AB9F-9C9F77936614
P2860
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
@ast
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
@en
type
label
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
@ast
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
@en
prefLabel
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
@ast
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
@en
P2093
P1476
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery
@en
P2093
P304
P356
10.1016/S1074-5521(00)80022-8
P577
1999-10-01T00:00:00Z